Arterial Aneurysms in Wegenerapos;s Granulomatosis: Case Report and Literature Review.
|
 | OBJECTIVE: Arterial aneurysms are characteristic of medium-size vessel vasculitis but are a very unusual feature of Wegeneramp;apos;s granulomatosis (WG). We describe a typical WG case, complicated by arterial aneurysms and review previously reported cases.
METHODS: Medline database search of cases published...more |
|
|
|
Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: early experience.
|
 | BACKGROUND: Tacrolimus (TAC) with mycophenolate mofetil (MMF) and a steroid-free regimen seems to have good efficacy in preventing acute rejection in cardiac transplant recipients, although concern exists about nephrotoxicity. Induction therapy with Daclizumab seems to give protection without side effects. Data are lacking about...more |
|
|
|
Renal function in patients with cadaveric kidney transplants treated with tacrolimus or cyclosporine.
|
 | INTRODUCTION: Renal function predicts graft survival in kidney transplant patients. This study compared the 2-year evolution of renal function in patients treated with cyclosporine or tacrolimus in combination with mycophenolate mofetil (MMF) and prednisone.
nbsp;
METHODS: We studied 1558 cadaveric renal...more |
|
|
|
IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkinapos;s lymphoma patients.
|
 | We explored the efficacy of the IGEV regimen (ifosfamide, gemcitabine, vinorelbine and prednisone) combined with a fixed dose of lenograstim (263 mug/day) to mobilize peripheral blood stem cells (PBSCs) in 90 Hodgkinamp;apos;s lymphoma patients. The median total CD34+ cells/mul peak, colony-forming units granulocyte-macrophage and white blood cells...more |
|
|
|
A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation.
|
BACKGROUND: The optimal maintenance immunosuppressive regimen after lung transplantation is uncertain.
nbsp;
METHODS: We conducted a randomized controlled trial of tacrolimus versus cyclosporine in combination with azathioprine and prednisone after lung transplantation. Ninety adults were randomized to tacrolimus...more |
|
|
Outcome of children with aplastic anemia treated with immunosuppressive therapy.
|
BACKGROUND: Immunosuppressive therapy (IST) is the alternative treatment in children with aplastic anemia (AA) who do not have an HLA-matched sibling. The aim of this study is to evaluate the outcome of children with AA treated with IST.
nbsp;
METHODS: We retrospectively reviewed the hospital records of children...more |
|
|
A case report of Hailey-Hailey disease treated with alefacept (Amevive((R))).
|
| Hailey-Hailey disease (chronic benign familial pemphigus) is a chronic, recurrent blistering disorder characterized clinically by erosions occurring primarily in intertriginous regions and histologically by suprabasilar acantholysis. We report a case of Hailey-Hailey disease initially unresponsive to multiple topical corticosteroids, tetracycline,...more |
|
|
Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
|
BACKGROUND: Treatment of early-stage Hodgkinamp;apos;s disease is usually tailored in line with prognostic factors that allow for reductions in the amount of chemotherapy and extent of radiotherapy required for a possible cure.
nbsp;
METHODS: From 1993 to 1999, we identified 1538 patients (age, 15 to 70 years)...more |
|
|
Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
|
| BACKGROUND: Treatment of early-stage Hodgkinamp;apos;s disease is usually tailored in line with prognostic factors that allow for reductions in the amount of chemotherapy and extent of radiotherapy required for a possible cure. METHODS: From 1993 to 1999, we identified 1538 patients (age, 15 to 70 years) who had untreated stage...more |
|
|
Independent Data Monitoring Board Recommends Expedited Interim Analysis Of Overall Survival Data For Satraplatin Phase 3 Trial
|
| As previously announced, following the interim efficacy analysis conducted on April 25, 2006, the DMB recommended that the SPARC trial continue as planned. The focus of that analysis was progression-free survival (PFS) and safety data. PFS remains the endpoint of the SPARC trial for accelerated approval in the U.S. and is also the basis, along with...more |
|
|
|
